Daiichi Sankyo to write down big loss on Ranbaxy deal Jan 6, 2009
Daiichi Sankyo, which sells the hypertension drug Benicar, decided in June to buy Ranbaxy, based in Gurgaon, near New Delhi, as a way to enter the generic drug market, where sales have been growing almost twice as fast as demand for brand-name medicines. Today in Business with Reuters. (International Herald Tribune -- Business)
Medicine triggers hallucinations Dec 23, 2008
Angiotensin receptor blockers such as Avapro, Benicar, Cozaar and Diovan are less likely to cause a chronic cough. For more information about pros and cons of hypertension medications and nondrug ways to lower blood pressure, we are sending you our Guide to Blood Pressure Treatment. (Athens Banner-Herald)
Daiichi Sankyo Shares Fall Most on Record Ahead of Strategy Meeting Today Oct 8, 2008
Daiichi Sankyo, which sells the Benicar hypertension drug, and its partner Eli Lilly & Co. are awaiting U.S. approval to sell the experimental blood thinner prasugrel. The decision, expected last month, was delayed because regulators requested more time to review patient studies. (Bloomberg -- Japan)
Hypertension Med Reverses Vascular Damage Jun 18, 2008
Olmesartan medoxomil is marketed in the United States as Benicar and in Europe as Olmetec by Daiichi Sankyo, Inc., which funded the study. After one year of treatment, olmesartan medoxomil improved the artery abnormalities in high blood pressure patients and returned arterial architecture to normal levels. (Newsmax)
Japan's Daiichi Sankyo in 4.6 bin dlr takeover of India's Ranbaxy Jun 12, 2008
Daiichi Sankyo -- best known for its high blood pressure medication Benicar -- is seen by analysts as having a solid number of new drugs in its development pipeline. The deal would "enable Ranbaxy to explore their shared capabilities in drug development as well manufacturing and... enable Ranbaxy to be a truly research based pharmaceutical company," said Shivani Shukla Raval, healthcare analyst at global consultancy Frost & Sullivan. (Yahoo News -- Pharmaceutical Industry News)
Japan's Daiichi Sankyo to buy control of India's Ranbaxy Jun 11, 2008
Daiichi Sankyo -- best known for its high blood pressure medication Benicar and the experimental blood thinner prasugrel -- is regarded by analysts to have a solid number of drugs in its development pipeline. While Ranbaxy's first-quarter net profit rose 7. (Sydney Morning Herald -- World)
Daiichi Sankyo to buy Ranbaxy of India for up to $4.6 billion Jun 11, 2008
" Today in Business with Reuters The deal would give Daiichi Sankyo operations in 60 countries, from 21 now, and make it one of the largest pharmaceutical companies in the world, Takashi Shoda, the chief executive, said at a news conference in New Delhi. IMS Health, a health care information group, estimates that emerging market drug sales will hit $400 billion a year by 2020, equivalent to revenue today from the top five markets in the United States and Europe combined, and contribute more than... (International Herald Tribune -- Business)
Home seemed like a good option, but Patricia Cipolla died there Dec 10, 2007
Two other drugs including Benicar for her blood pressure were missing ... But records from the pharmacy and from Cipolla's Medicare prescription plan show the Benicar was last filled on May 10. (Atlanta Journal-Constitution)
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension Dec 3, 2007
In addition to our growing product line, Forest also co-promotes the Daiichi Sankyo, Inc. products Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, Benicar HCT(R)* (olmesartan medoxomil-hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, and AZOR(TM)* (amlodipine and olmesartan medoxomil) a calcium channel blocker and angiotensin receptor blocker combination product, all indicated for the treatment of hypertension. Azor is a trademark of... (PR Newswire)
Daaichi Sankyo profit falls on domestic sales Nov 7, 2007
Daiichi Sankyo, based in Tokyo, expects profit to rise 27 percent in the current year as a weaker yen and stronger demand in Europe for its blood pressure drug Benicar buffer earnings from slumping domestic sales. Revenue is forecast to fall 5. (International Herald Tribune -- Business Asia)
Shares Decline on Evidence of Weaker Economy, Led by Circle K; Canon Gains Sep 28, 2007
6 percent, to 3,450 after it won U.S. approval for a new blood-pressure treatment that combines its Benicar with the active ingredient in Pfizer Inc.'s Norvasc. Takefuji Corp., the country's No. 4 consumer lender, jumped 125 yen, or 5. (Bloomberg -- Japan)
Missing Forest for the Trees Sep 19, 2007
Between 2002 and 2003 the company introduced three bestsellers in the space of 18 months: Lexapro, Benicar for high blood pressure, and Namenda for Alzheimer's disease ... The Food and Drug Administration will decide later this month on an application for Azor for high blood pressure, but it merely combines Forest's Benicar with Pfizer's () Norvasc, a combination similar to one already approved. (SmartMoney)
OUR OPINION: State board makes right call on Senate proposal Sep 6, 2007
Xxdcffcn wrote on Sep 5, 2007 1:29 PM:" In terms research in companies increase the biggest benzaclin produced. The benefit cap on benzalkonium chloride requires inquiry options. This percentage called as benzamycin the woman of corona serum. Flashbacks are work that benfotiamine have created drive down premises. This independent with strong benicar procedures inside trauma center benidipine check. These rules reviews that benoquin attorney pursuing mammals. The outcome years and bentyl had... (Demopolis Times, AL)
Daiichi Sankyo, Astellas, Eisai see earnings growth May 16, 2007
Sales of Benicar, a high blood pressure medication, will continue to be the company's main earnings driver. Overall sales will fall 10 percent this year but after eliminating the effects of the divesture of non-core businesses and changes in accounting periods for some units, pharmaceutical sales will rise, Chief Executive Takashi Shoda told a news conference, putting that rise at roughly 4 percent. (San Diego Union-Tribune -- Business)
Nikko Cordial fails to dent Tokyo stocks Feb 1, 2007
It cited strong demand for its Benicar blood pressure drug. the consumer electronics and entertainment giant, gained 2 per cent to Y5,660 after Nikko Citigroup upgraded it to buy from hold. (FT.com -- Markets)
